PE20160882A1 - Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal - Google Patents

Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal

Info

Publication number
PE20160882A1
PE20160882A1 PE2016000430A PE2016000430A PE20160882A1 PE 20160882 A1 PE20160882 A1 PE 20160882A1 PE 2016000430 A PE2016000430 A PE 2016000430A PE 2016000430 A PE2016000430 A PE 2016000430A PE 20160882 A1 PE20160882 A1 PE 20160882A1
Authority
PE
Peru
Prior art keywords
bowel syndrome
irritable bowel
antibodies
diagnosis
treatment
Prior art date
Application number
PE2016000430A
Other languages
English (en)
Spanish (es)
Inventor
Mark Pimentel
Christopher Chang
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52813648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160882(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of PE20160882A1 publication Critical patent/PE20160882A1/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • G01N33/487Physical analysis of biological material of liquid biological material
    • G01N33/49Blood
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/06Gastro-intestinal diseases
    • G01N2800/065Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Ecology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
PE2016000430A 2013-10-09 2014-10-09 Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal PE20160882A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361888658P 2013-10-09 2013-10-09

Publications (1)

Publication Number Publication Date
PE20160882A1 true PE20160882A1 (es) 2016-09-14

Family

ID=52813648

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000430A PE20160882A1 (es) 2013-10-09 2014-10-09 Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal

Country Status (19)

Country Link
US (2) US9851361B2 (https=)
EP (1) EP3054977B1 (https=)
JP (1) JP6567509B2 (https=)
KR (1) KR102259588B1 (https=)
CN (1) CN105744956B (https=)
AU (2) AU2014331841B2 (https=)
BR (1) BR112016007474A2 (https=)
CA (1) CA2923651C (https=)
CL (1) CL2016000820A1 (https=)
ES (1) ES2892905T3 (https=)
IL (1) IL244971B2 (https=)
MX (1) MX383423B (https=)
NZ (1) NZ717633A (https=)
PE (1) PE20160882A1 (https=)
PL (1) PL3054977T3 (https=)
PT (1) PT3054977T (https=)
RU (1) RU2683781C2 (https=)
SG (1) SG11201601733VA (https=)
WO (1) WO2015054529A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9851361B2 (en) 2013-10-09 2017-12-26 Cedars-Sinai Medical Center Methods of comparing anti-vinculin and anti-cytolethal distending toxin antibodies as they relate to irritable bowel syndrome
US9952223B2 (en) 2012-09-17 2018-04-24 Cedars-Sinai Medical Center Method for detecting anti-vinculin antibodies in a subject with an IBS symptom
US10132814B2 (en) 2014-10-09 2018-11-20 Cedars-Sinai Medical Center Methods for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
US10151752B2 (en) 2009-02-11 2018-12-11 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US12222352B2 (en) 2017-01-30 2025-02-11 Cedars-Sinai Medical Center Diagnosis of scleroderma

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
CN106053827A (zh) * 2016-05-17 2016-10-26 上海凯璟生物科技有限公司 一种肠易激综合症标志物Vinculin抗体检测试剂盒及其制备方法
CN105784989A (zh) * 2016-05-17 2016-07-20 上海凯璟生物科技有限公司 一种肠易激综合症标志物CdtB抗体检测试剂盒及其制备方法
KR102481305B1 (ko) * 2016-05-20 2022-12-26 세다르스-신나이 메디칼 센터 유전자에 기반한 염증성 장 질환의 진단
RU2763258C1 (ru) * 2020-07-13 2021-12-28 Евгения Николаевна Воронина Способ дифференциальной диагностики воспалительных заболеваний кишечника у детей по комплексу клинико-анамнестических, лабораторных и инструментальных критериев

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691151A (en) * 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
FR2806805A1 (fr) 2000-03-22 2001-09-28 Centre Nat Rech Scient SEQUENCE PEPTIDIQUES COMPRENANT UN OU PLUSIEURS MOTIFS DE LIAISON AUX PROTEINES DE LA FAMILLE Ena/VASP, ET LEURS UTILISATIONS
US20040018528A1 (en) * 2002-05-17 2004-01-29 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
WO2004024097A2 (en) 2002-09-16 2004-03-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7595386B2 (en) 2003-01-24 2009-09-29 William Beaumont Hospital Methods and compositions for heat activated gene therapy using cytolethal distending toxin
MXPA05010819A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
EP2287616A1 (en) * 2003-09-15 2011-02-23 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate systemic lupus erythematosus
DK1698698T3 (da) 2003-12-05 2014-05-12 Fuso Pharmaceutical Ind Cytolethaldistenderende toksingener som mål for detektering af campylobacterbakterier
US8148067B2 (en) 2006-11-09 2012-04-03 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
CA2747253A1 (en) 2007-12-20 2009-07-02 Index Diagnostics Ab Method and kit for use in the differentiation of ibd and ibs and further distinction between disease types of ibd
EP2370435B1 (en) 2008-11-24 2015-01-07 Cedars-Sinai Medical Center Antioxidant camptothecin derivatives and antioxidant antineoplastic nanospheres thereof
CA2752020A1 (en) 2009-02-11 2010-08-19 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
EP2396652B1 (en) 2009-02-11 2017-12-13 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel syndrome based on cytolethal distending toxin
FR2942541A1 (fr) 2009-02-25 2010-08-27 Assist Publ Hopitaux De Paris Procede de diagnostic d'une vascularite
RU2397178C1 (ru) * 2009-02-27 2010-08-20 Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Диагностическая тест-система в формате иммуночипа и способ серологической дифференциальной диагностики сифилиса
IT1400989B1 (it) 2010-07-13 2013-07-05 Segix Italia S R L Ora Istituto Biochimico Naz Savio S R L Forme di somministrazione orale a rilascio controllato di rifampicina per il trattamento di infezioni batteriche dell' apparato intestinale.
GB201017520D0 (en) 2010-10-15 2010-12-01 Sense Proteomic Ltd Biomarkers
US9702884B2 (en) * 2012-09-17 2017-07-11 Cedars-Sinai Medical Center Methods for detecting the presence of irritable bowel syndrome and system for diagnosing same
PT3054977T (pt) 2013-10-09 2021-10-14 Cedars Sinai Medical Center Diagnóstico e tratamento da síndrome do intestino irritável e da doença inflamatória intestinal
WO2016057772A1 (en) 2014-10-09 2016-04-14 Cedars-Sinai Medical Center Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
CN106091069A (zh) 2016-06-15 2016-11-09 安徽省绿巨人环境技术有限公司 一种废水再利用装置
JP2020507755A (ja) 2017-01-30 2020-03-12 シーダーズ−サイナイ メディカル センター 強皮症の診断法

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10151752B2 (en) 2009-02-11 2018-12-11 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US10527621B2 (en) 2009-02-11 2020-01-07 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US9952223B2 (en) 2012-09-17 2018-04-24 Cedars-Sinai Medical Center Method for detecting anti-vinculin antibodies in a subject with an IBS symptom
US9851361B2 (en) 2013-10-09 2017-12-26 Cedars-Sinai Medical Center Methods of comparing anti-vinculin and anti-cytolethal distending toxin antibodies as they relate to irritable bowel syndrome
US10352944B2 (en) 2013-10-09 2019-07-16 Cedars-Sinai Medical Center Method of determinig levels of anti-vinculin and anti-cytolethal distending toxin antibodies in subjects desiring to distinguish irritable bowel syndrome from inflammatory bowel disease
US10132814B2 (en) 2014-10-09 2018-11-20 Cedars-Sinai Medical Center Methods for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
US12222352B2 (en) 2017-01-30 2025-02-11 Cedars-Sinai Medical Center Diagnosis of scleroderma

Also Published As

Publication number Publication date
CL2016000820A1 (es) 2016-09-23
ES2892905T3 (es) 2022-02-07
KR102259588B1 (ko) 2021-06-02
IL244971B2 (en) 2023-12-01
AU2014331841B2 (en) 2020-03-12
AU2020203468A1 (en) 2020-06-18
EP3054977A4 (en) 2017-04-12
IL244971A0 (en) 2016-05-31
HK1221898A1 (zh) 2017-06-16
CA2923651C (en) 2023-03-14
JP2017502253A (ja) 2017-01-19
US20180196063A1 (en) 2018-07-12
PL3054977T3 (pl) 2021-12-20
BR112016007474A2 (pt) 2017-09-12
RU2683781C2 (ru) 2019-04-02
EP3054977A1 (en) 2016-08-17
CN105744956A (zh) 2016-07-06
SG11201601733VA (en) 2016-04-28
WO2015054529A1 (en) 2015-04-16
CA2923651A1 (en) 2015-04-16
US9851361B2 (en) 2017-12-26
MX383423B (es) 2025-03-14
MX2016004167A (es) 2016-06-24
CN105744956B (zh) 2021-07-20
NZ717633A (en) 2021-07-30
JP6567509B2 (ja) 2019-08-28
PT3054977T (pt) 2021-10-14
EP3054977B1 (en) 2021-07-21
RU2016116766A (ru) 2017-11-15
AU2014331841A1 (en) 2016-03-24
KR20160062161A (ko) 2016-06-01
IL244971B1 (en) 2023-08-01
US10352944B2 (en) 2019-07-16
US20170038393A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
PE20160882A1 (es) Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal
MX387936B (es) Metodo para la cuantificacion de huevos de parasitos en las heces.
BR112016019836A2 (pt) método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito
MX2018002400A (es) Receptores de antigenos quimericos condicionalmente activos para celulas t modificadas.
MX374652B (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco.
MX367046B (es) Marcadores especificos de via para diagnosticar sindrome del intestino irritable.
MX355020B (es) Biomarcadores de cancer de pulmon y usos de los mismos.
EA201792497A1 (ru) Антитела к gitr для диагностики злокачественной опухоли
BR112015019614A8 (pt) análise de imagens e medições de amostras biológicas
BR112015022490A2 (pt) métodos e composições para classificação de amostras
MX2016013255A (es) Metodos y composiciones para detectar proteinas mal plegadas.
MX2016002537A (es) Anticuerpos y ensayos para la detección del receptor 1 de folato.
EA201500080A1 (ru) Способ in vitro диагностирования и мониторинга рака
WO2016198833A3 (en) Methods for analysing a urine sample
MX2017014196A (es) Deteccion de factores de virulencia microbiana bucal.
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
BR112015004800A2 (pt) método e aparelho para examinar ovos
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
TR201903974T4 (tr) Tasnif makinesi için otomatik kusur tanı metodu ve cihazı.
CL2011001944A1 (es) Metodo de diagnostico in vitro de un sujeto con sindrome de intestino irritable (ibs).
MX384921B (es) Métodos y sistemas para distinguir el síndrome del intestino irritable de la enfermedad inflamatoria intestinal y la enfermedad celíaca.
EA201790696A1 (ru) Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности
GB2545850A (en) System and method using a combined modality optical probe
MX2018002467A (es) Anticuerpos y ensayos para deteccion del antigeno leucocitico (cd37).
BR112016017901A2 (pt) ensaio inovador para detectar periostina humana